Comparison of Hepatus and FibroScan for Evaluation of Fibrosis and Steatosis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

400 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-12-29

Study Completion Date

2024-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Totals of 400 chronic hepatitis B or non-alcoholic fatty liver disease (NAFLD) patients with or without cirrhosis will be enrolled. Patients' clinical characteristics, including alanine aminotransferase, aspartic aminotransferase, total bilirubin, direct bilirubin, indirect bilirubin, triglyceride and total cholesterol, hepatitis B surface antigen, steatosis, and liver stiffness measurement will be collected. The consistence of liver fibrosis and steatosis assessment between Hepatus and FibroScan will be evaluated in this study.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Clinical Application of Non-invasive Assessment for Staging Liver Steatosis and Liver Fibrosis

NCT03386890

Nonalcoholic Fatty Liver Disease Liver Steatosis Liver Fibrosis

UNKNOWN

Prospective Study In Noninvasive Evaluation of Hepatic Fibrosis in Chronic Hepatitis B

NCT01679769

Chronic Hepatitis B

COMPLETED

FibroTouch Non-invasive Evaluation of Liver Fibrosis and Cirrhosis

NCT02476695

Liver Fibrosis Cirrhosis Chronic Hepatitis B

COMPLETED

68Ga-FAPI PET/CT in Liver Fibrosis Patients

NCT04533828

Liver Fibrosis Positron Emission Tomography

UNKNOWN EARLY_PHASE1

Prospective Stuy in Evaluating Hepatic Fibrosis Related to Hepatitis B Virus Using Non-invasive Parameters

NCT01962155

Hepatitis B Liver Fibrosis

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Hepatitis b Non-Alcoholic Fatty Liver Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

CROSS_SECTIONAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with or without cirrhosis diagnose as chronic hepatitis B or non-alcoholic fatty liver disease;
* Age above 18 years;
* Signature of informed consent.

Exclusion Criteria

* Patients with HCV and/or other viral hepatitis, autoimmune liver disease, alcoholic liver disease, genetic liver disease or other chronic liver diseases;
* Patients with decompensated cirrhosis;
* Patients with serum total bilirubin level higher than 51 umol/L;
* Patients with liver malignant lesion, hemangiomas, giant liver cysts and other liver lesions;
* Patients with HIV infections;
* Patients after liver transplantation or TIPS;
* Pregnant women;
* Patients with Budd-Chiari syndrome, chronic congestive heart failure, constrictive pericarditis or other liver congestion lesions.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No